NEXT Financial Group Inc lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 49.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 29,452 shares of the biopharmaceutical company’s stock after selling 28,786 shares during the period. NEXT Financial Group Inc’s holdings in Pfizer were worth $1,067,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Beach Investment Management LLC. bought a new position in shares of Pfizer during the 2nd quarter valued at about $5,214,000. Pinnacle Financial Partners Inc. lifted its holdings in shares of Pfizer by 36.2% during the 2nd quarter. Pinnacle Financial Partners Inc. now owns 120,651 shares of the biopharmaceutical company’s stock valued at $4,053,000 after purchasing an additional 32,089 shares in the last quarter. Conning Inc. lifted its holdings in shares of Pfizer by 3.5% during the 2nd quarter. Conning Inc. now owns 1,189,755 shares of the biopharmaceutical company’s stock valued at $39,964,000 after purchasing an additional 39,985 shares in the last quarter. Donaldson Capital Management LLC lifted its holdings in shares of Pfizer by 2.1% during the 2nd quarter. Donaldson Capital Management LLC now owns 624,744 shares of the biopharmaceutical company’s stock valued at $20,985,000 after purchasing an additional 12,766 shares in the last quarter. Finally, Dupont Capital Management Corp lifted its holdings in shares of Pfizer by 9.1% during the 2nd quarter. Dupont Capital Management Corp now owns 440,449 shares of the biopharmaceutical company’s stock valued at $14,795,000 after purchasing an additional 36,605 shares in the last quarter. Hedge funds and other institutional investors own 71.41% of the company’s stock.
Several research firms have recently weighed in on PFE. Sanford C. Bernstein set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. Goldman Sachs Group set a $36.00 price objective on Pfizer and gave the company a “neutral” rating in a report on Tuesday, January 30th. UBS Group set a $42.00 target price on Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. BMO Capital Markets set a $39.00 target price on Pfizer and gave the company a “buy” rating in a research report on Tuesday, January 30th. Finally, Deutsche Bank set a $38.00 target price on Pfizer and gave the company a “buy” rating in a research report on Wednesday, December 6th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $39.40.
Pfizer Inc. (PFE) opened at $36.58 on Friday. The firm has a market capitalization of $217,760.00, a P/E ratio of 20.90, a price-to-earnings-growth ratio of 2.07 and a beta of 0.91. Pfizer Inc. has a 1 year low of $31.67 and a 1 year high of $39.43. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.47 EPS. sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd were given a dividend of $0.34 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend was Thursday, February 1st. This represents a $1.36 annualized dividend and a dividend yield of 3.72%. Pfizer’s payout ratio is 77.71%.
Pfizer declared that its board has authorized a stock buyback program on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s leadership believes its shares are undervalued.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.